Clinical Trials Logo

Lung Diseases, Interstitial clinical trials

View clinical trials related to Lung Diseases, Interstitial.

Filter by:

NCT ID: NCT02370693 Completed - Systemic Sclerosis Clinical Trials

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.

NCT ID: NCT02370550 Recruiting - Sjogren's Syndrome Clinical Trials

Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome

CTRIPS
Start date: March 2015
Phase: Phase 4
Study type: Interventional

The purpose of this large multicenter, randomized, double-blinded, controlled clinical study is to investigate the efficacy and safety of Cyclosporin A for primary Sjogren's syndrome associated pneumonitis(pSS-IP), which has important implications for the establishment of standardized diagnosis and treatment of pSS-IP.

NCT ID: NCT02369575 Recruiting - Clinical trials for Lung Diseases, Interstitial

Identification of Novel Markers of Human Lung Disease

Start date: February 2015
Phase:
Study type: Observational

The purpose of this study is to investigate new therapies for advanced lung disease.

NCT ID: NCT02278107 Enrolling by invitation - Clinical trials for Interstitial Lung Disease

Evaluation of a Lightweight Nasal Interface and Ventilator in Patients With Respiratory Disease

Start date: July 2014
Phase: N/A
Study type: Interventional

A preliminary study to evaluate a new nasal interface and portable ventilator system in comparison to standard oxygen therapy in patients with severe chronic lung disease.

NCT ID: NCT02251964 Completed - Clinical trials for Lung Diseases, Interstitial

Rituximab in Interstitial Pneumonitis

RITUX-IP
Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This project will address rare immune mediated inflammatory diseases (IMIDs) involving the lungs, i.e. interstitial pneumonitis (IP). The main objective of this study is to assess the effects of rituximab (RTX) as a rescue therapy for progressive IMID-IP patients. The primary study parameter is pulmonary function. The secondary objectives are to explore the application of imaging with radiolabeled RTX as early predictor for efficacy of RTX, to study the effects of RTX treatment on quality of life, and to further elucidate the pathophysiology of IMID-IP by analyzing biochemical markers.

NCT ID: NCT02246023 Completed - Lung Cancer Clinical Trials

Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy

Start date: January 2015
Phase: Phase 4
Study type: Interventional

After randomization, the subjects undergo flexible bronchoscopy either with fractionated propofol administration or with propofol-TCI. Measurement of blood pressure, heart rate, oxygen saturation, and oxygen requirement are measured continuously during the procedure and thereafter. Cumulative propofol dose, and induction, procedure, and recovery time are noted continuously during and after the procedure.

NCT ID: NCT02235779 Recruiting - Clinical trials for Interstitial Lung Disease

Diagnostic Yield of Transbronchial Cryobiopsy in Diagnosis of Interstitial Lung Diseases

Start date: August 2014
Phase: N/A
Study type: Interventional

Evaluation of diagnostic yield, feasibility and safety of transbronchial lung cryobiopsies done via bronchoscopy in the investigation of interstitial lung disease in comparison with videothoracoscopy-assisted surgical lung biopsy.

NCT ID: NCT02229994 Completed - Clinical trials for Cystic Fibrosis of the Adult

Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases

DYSLIM
Start date: March 16, 2010
Phase: N/A
Study type: Observational

The purpose of this study is the psychometric validation of a self-administered dyspnea questionnaire, usable in clinical practice in order to assess dyspnea and its impact on patients with chronic respiratory diseases.

NCT ID: NCT02201654 Completed - Clinical trials for Interstitial Lung Disease

Stylet vs No Stylet During EBUS TBNA

Start date: June 2014
Phase: N/A
Study type: Interventional

This research study compares two ways to biopsy lymph nodes in the chest using endobronchial ultrasound-guided transbronchial needle aspiration" (EBUS-TNBA). During a EBUS-TBNA procedure, the patient is sedated, and a flexible camera and ultrasound probe is inserted through the mouth into the large airways of the chest, allowing us to see (via ultrasound) and biopsy the lymph nodes in the chest. The purpose of this research study is to determine if the EBUS-TBNA procedure can be made simpler. In today's practice, the biopsy needle has two parts, 1) the needle itself and 2) an inner stylet that runs through the middle of the needle. Because many other biopsy needles (such as the needles used in breast biopsy and different types of lung biopsy needles) do not use an inner stylet, the investigators do not think the use of a stylet is necessary. If this step can be safely eliminated without decreasing the effectiveness of the procedure, this could shorten the procedure (saving time). This study is deigned to formally test the hypothesis that a stylet is not necessary in EBUS-TBNA.

NCT ID: NCT02197364 Completed - Clinical trials for Interstitial Lung Disease

The Role of KL-6 in the Clinical Diagnosis of ILD

Start date: December 2013
Phase: N/A
Study type: Observational

The purpose of the study is to evaluate the significance of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases. In addition, the study discusses the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and after treatment.